Howard B. Goldman Joins the Clinical Advisory Board, and Other Highlights of 2025

21. January 2026

We are proud to welcome Howard B. Goldman as the newest member of InnoCon Medical’s Clinical Advisory Board. Dr. Goldman is a Professor at the Cleveland Clinic Lerner College of Medicine, where he serves as Vice Chairman for Clinical Affairs at the Glickman Urologic Institute. He is also Fellowship Director in Female Pelvic Medicine and Reconstructive Surgery within the Departments of Urology and Obstetrics & Gynecology, and Chair of the Education Committee of the International Continence Society. Dr. Goldman has a long-standing clinical and research interest in the dorsal genital nerve (DGN) as a potential target for neuromodulation in refractory overactive bladder (OAB) symptoms.

Throughout the year, UCon was evaluated across several clinical studies. Early in 2025, researchers from University College London (UCL) and Royal National Orthopaedic Hospital NHS Trust published their evaluation of the UCon system in participants with spinal cord injury. Later in the year, collaborators from Radboud University Medical Center reported results from a pilot study on dorsal genital nerve stimulation (DGNS) for patients with Persistent Genital Arousal Disorder (PGAD).

The most recent publication from a Danish feasibility study on DGNS in patients with fecal incontinence (FI) and fecal urgency (FU) was published in Neurogastroenterology & Motility, reporting on safety, feasibility, and clinical outcomes. The study demonstrated, among other findings, significant reductions in FI episodes and strong FU episodes.

In August, Yan Peng, MD, from the Fifth Affiliated Hospital of Zhengzhou University, visited Denmark to share clinical experience using UCon in spinal cord injury patients in China. The therapy was reported to be well tolerated, with preliminary observations indicating improvements in bladder capacity in all selected patients.

In addition, the University of Michigan enrolled its first patient in a clinical study investigating dorsal genital nerve stimulation with UCon for female sexual dysfunction. Several additional clinical studies remain ongoing, including a randomized controlled trial in Denmark conducted in collaboration with Herlev Hospital, Aarhus University Hospital, and Odense University Hospital.

InnoCon Medical thanks its collaborating clinicians, advisors, and research partners for their continued engagement and looks ahead to further clinical progress in 2026.

Howard B. Goldman, MD, FACS, the newest addition to InnoCon Medical’s Clinical Advisory Board.

Image of Yan Peng, MD, with Nico Rijkhoff and Dianna Mærsk Knudsen holding the UCon neuromodulation system.

Dr. Yan Peng, Orthopedic Director and Chief Physician, with Nico Rijkhoff and Dianna Mærsk Knudsen, following a presentation on Dr. Peng’s clinical experience using InnoCon Medical’s UCon system for dorsal genital nerve stimulation (DGNS) in patients with spinal cord injury.

Dr. Louise Schmidt Grau at ESCP 2025 Paris

UCon-related research was presented at multiple international conferences throughout the year. InnoCon Medical’s long-term collaborator, Dr. Louise Schmidt Grau, shared clinical findings at ESCP 2025, DKS, and other professional meetings.

Pictured are principal investigator Priyanka Gupta, MD, flanked by co-investigators Tim Bruns, BME PhD, and BME PhD student Sonia Bhaskaran. They are holding the UCon neuromodulation system in their hands.

The team at the University of Michigan, Ann Arbor: Principal Investigator Priyanka Gupta, MD, with co-investigators Tim Bruns, PhD, and Sonia Bhaskaran, PhD student in Biomedical Engineering.

Chinese patent certificate granted to InnoCon Medical.

InnoCon Medical has secured patents in multiple countries, including the US, Australia, India, Korea, and several European countries, with Japan added to the list in 2025. Pictured is the Chinese patent certificate.